Диссертация (1139554), страница 55
Текст из файла (страница 55)
Anti-tumor activity of patient-derived NK cellsafter cell-based immunotherapy – a case report. // J Transl Med. 2009; 7:50.278. Miller J.S., Soignier Y. Successful adoptive transfer and in vivo expansion of humanhaploidentical NK cells in patients with cancer. // Blood. 2005; 105(8): 3051-3057.279. Min C., Yongyan C., Weihua X., Rui S., Zhigang T. NK cell-based immunotherapyfor malignant diseases. // Cellular and Molecular Immunology. 2013; 1-23.280. Moretta L. Dissecting CD56dim human NK cells.
// Blood. 2010; 116(19): 36893691.281. Moretta L., Bottino C., Pende D. et al. Human NK cells: molecular mechanisms controlling NK cell activation and tumor cell lysis. // Imm Lett. 2005; 100: 7-13.282. Moretta L., Pietra G., Montaldo E. et al. Human NK cells: from surface receptors tothe therapy of leukemias and solid tumors. // Front in Immunol. 2014; 5: 87.283.
Murray S., Lundqvist A. Targeting the tumor microenvironment to improve naturalkiller cell-based immunotherapies: on being in the right place at the right time, withresilience. // Human vaccines and Immunotherapeutics. 2016; 12(3): 607-611.284. Naora H., Gougeon M. Activation, survival and apoptosis of CD45RO+ andCD45RO- T cells of human immunodeficiency virus-infected individuals: effects ofinterleukin-15 and comparison with interleukin-2. // Immunol. 1999; 97(2): 181-187.285. Navarro G.A., Bjorklund A.T., Chekenya M.
Therapeutic potential and challenges of284natural killer cells in treatment of solid tumors. // Front in Immunol. 2015; 6: 202.286. Nestle F.O., Dummer R. New perspectives on immunobiology and immunotherapyof melanoma. // Immunology Today. 1998; 20(1): 5-7.287. Nishino M., Giobbie-Hurder A., Gargano M.
et al. Developing a common languagefor tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. // Clinical Cancer Research. 2013; 19(14): 3936-3943.288. Nuckel H., Switala M., Sellmann L. et al. The prognostic significance of solubleNKG2D ligands in B-cell chronic lymphocytic leukemia. // Leukemia.
2010; 24(6):1152-1159.289. O’Leary J.G., Goodarzi M., Drayton D.L., von Andrian U.H. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. // Nature Immunology.2006; 7: 507-516.290. Ogbomo H., Hahn A., Geiler J. et al. NK sensitivity of neuroblastoma cells determined by a highly sensitive coupled luminescent method.
Biochemical and Biophysical Research Communications. 2006; 339 (1): 375-379.291. Orange J.S., Ballas Z.K. Natural killer cells in human health and disease. // ClinicalImmunology. 2006; 118: 1-10.292. Packard B.Z., Telford W.G., Komoriya A., Henkart P.A. Granzyme B activity in target cells detects attack by cytotoxic lymphocytes. // Immunology. 2007; 179: 38123820.293. Paradopoulos N.G., Dedoussis G.V.Z., Spanakos G.
et al. An improved fluorescenceassay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. // Immunological methods. 1994; 177: 101-111.294. Pardoll D. Immunology. Stress, NK receptors, and immune surveillance. // Science.2001; 294: 534-538.295. Park M.J., Bae J.H., Chung J.S. et al. Induction of NKG2D ligands and increasedsensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrinbased photodynamic therapy. // Immunol Investigat.
2011; 40: 367-382.296. Parkhurst M.R., Riley J.P., Dudley M.E., Rosenberg S.A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but doesnot mediate tumor regression. // Clin Cancer Research. 2011: 17:6287–97.285297. Paschen A., Sucker A., Hill B. et al. Differential clinical significance of individualNKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
// Clinical Cancer Research. 2009: 15(16): 5208-5215.298. Paust S., Gill H.S., Wang B.Z. et al. Critical role for the chemokine receptor CXCR6in NK cell-mediated antigen-specific memory of haptens and viruses. // Nature Immunology. 2010; 11(12): 1127-1135.299. Penack O., Gentilini C., Fischer L. et al. CD56dimCD16neg cells are responsible fornatural cytotoxicity against tumor targets. // Leukemia. 2005; 19 (5): 835-840.300. Pende D., Rivera P., Marcenaro S. et al.
Major histocompatibility complex class Irelated chain A and UL16-binding protein expression on tumor cell lines of differenthistotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cellcytotoxicity. // Cancer Research. 2002; 62:6178-6186.301. Penn I. Development of cancer as a complication of clinical transplantation. // Transplantation Proceedings. 1977; 9(1): 1121-1127.302.
Phan G.Q., Rosenberg S.A. // Cancer Control. 2013; 20: 289-297.303. Pogge von Strandmann E., Simhadri V.R., von Tresckow B. et al. Human leukocyteantigen-B-associated transcript 3 is released from tumor cells and engages the NKp30receptor on natural killer cells. // Immunity. 2007; 27: 965-974.304. Porcu-Buisson G., Lambert M., Lyonnet L. et al. Soluble MHC Class I chain-relatedmolecule serum levels are predictive markers of implantation failure and successfulterm pregnancies following IVF. // Human Reproduction. 2007; 22:2261-2266.305. Porter D.L., Levine B.L., Kalos M.
et al. Chimeric antigen receptor–modified T cellsin chronic lymphoid leukemia. // Engl J Med. 2011; 365: 725-733.306. Pyo C.W., Guethlein L.A., Vu Q. et al. Different patterns of evolution in the centromeric and telomeric regions of group A and B haplotypes of the human killer cell Iglike receptor locus. // PloS one. 2010; 5: e15115.307. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. // Cell. 2010; 141: 39-517.308. Raffaghello L., Prigione I., Airoldi I.
et al. Downregulation and/or release of NKG2Dligands as immune evasion strategy of human neuroblastoma. // Neoplasia. 2004; 6:558-568.286309. Ralainirina N., Poli. A., Michel. T. et al. Control of NK cell functions byCD4+CD25+ regulatory T cells. // Leukocyte Biology. 2007; 81: 144-153.310. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands.
// Nature ReviewsImmunology. 2003; 3(10): 781-790.311. Raulet D.H., Vance R.E. Self-tolerance of natural killer cells. // Nature Reviews Immunology. 2006; 6: 520-531.312. Rayner A.A., Grimm E.A., Lotze M.T. Lymphokine-activated killer (LAK) cells.Analysis of factors relevant to the immunotherapy of human Cancer. // Cancer. 1985;55(6): 1327-1333.313. Rebmann V., Schutt P., Brandhorst D. et al.
Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. // Clinical Immunology. 2007; 123: 114-120.314. Rezaei N., Mahmoudi E., Aghamohammadi A. et al. X-linked lymphoproliferativesyndrome: a genetic condition typified by the triad of infection, immunodeficiencyand lymphoma. // British Journal of Haematology. 2011; 152: 13-30.315. Rezvani K., Rouce R.H. The Application of Natural Killer Cell Immunotherapy forthe Treatment of Cancer. // Frontiers in Immunology.
2015; 6: 578.316. Rizzieri D.A., Storms R., Chen D.F. et al. Natural killer cellenriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation // Biol Blood Mar Transpl. 2010; 16:110714.317. Robbins P.F., Morgan R.A., Feldman S.A. et al. Tumor regression in patients withmetastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. // Clinical Oncology.
2011; 29(7): 917-924.318. Rodella L., Zamai L., Rezzani R. et al. Interleukin 2 and interleukin 15 differentiallypredispose natural killer cells to apoptosis mediated by endothelial and tumour cells.// British Journal of Haematology. 2001; 115(2): 442-450.319. Roder J.C., Haliotis T., Klein M. et al. A new immunodeficiency disorder in humansinvolving NK cells.
// Nature. 1980; 284(5756): 553–555.320. Romagnani C., Juelke K., Falco M. et al. CD56bright CD56-killer Ig-like receptor287NK cells display longer telomeres and acquire teatures CD56dim NK cells upon activation. // Immunology. 2007; 178(8): 4947-4955.321. Romagne F., Andre P., Spee P. et al. Preclinical characterization of 1-7F9, a novelhuman anti-KIR receptor therapeutic antibody that augments natural killer-mediatedkilling of tumor cells.
// Blood. 2009; 114: 2667-2677.322. Romee R., Schneider S.E., Leong J.W. et al. Cytokine activation induces humanmemory-like NK cells. // Blood. 2012; 120: 4751-4760.323. Rosenberg S.A. Principles and practice of the biological therapy of cancer. 3rd edition– Lippincot Williams and Wilkins, 2000. 916 p.324. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients withmetastatic melanoma. // Current Opinion in Immunology.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
